GlassScriptPhysician profile
Julie Rodman
NPI 1679673313
$205,299.51
in general payments reported to CMS, 2019-2025
20 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $27K · 2021: $14K · 2022: $45K · 2023: $21K · 2024: $51K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $25K · Food and Beverage: $21K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Travel and Lodging: $6,226 · Honoraria: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,850.50 |
| Consulting Fee | $24,891.00 |
| Food and Beverage | $20,798.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,487.00 |
| Travel and Lodging | $6,226.16 |
| Honoraria | $2,919.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optovue, INC. | $58,012.47 | 2019-2021 | |
| Visionix USA, INC | $44,147.49 | 2022-2024 | Optical Coherence Tomography Hoct-1f |
| Apellis Pharmaceuticals, INC. | $37,956.29 | 2023-2025 | Syfovre, Syfovre |
| Astellas Pharma US INC | $32,386.03 | 2023-2025 | Izervay |
| Lkc Technologies, INC. | $21,264.66 | 2022-2023 | |
| Maculogix, INC. | $6,026.33 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $4,385.47 | 2023-2024 | Eylea |
| Notal Vision, INC. | $405.43 | 2025 | Foresee Home |
| Johnson & Johnson Vision Care, INC. | $221.39 | 2019-2022 | |
| Genentech, INC. | $97.66 | 2023 | Susvimo, Vabysmo |
| Astellas US LLC | $94.59 | 2024 | Izervay |
| Abbvie INC. | $64.24 | 2022-2024 | Vuity |
| Alcon Vision LLC | $62.88 | 2024 | Clareon |
| Allergan, INC. | $34.62 | 2019-2021 | |
| Rxsight INC | $33.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.62 | 2022 | |
| Quidel Corporation | $26.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.97 | 2019 | |
| Biotissue Holdings INC. | $16.62 | 2025 | |
| Oyster Point Pharma, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Rodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.